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p53mor viruses (the polyomaviruses, the adenoviruses and the papillomaviruses)
have led to fundamental discoveries that have advanced our understanding of basic mammalian cell
molecular biology processes such as transcription and DNA replication, uncovered pathways and genes often
perturbed in human cancer, and identiﬁed bona ﬁde human cancer viruses. In this article we examine the
many contributions that have come from the small DNA tumor virus ﬁeld and provide a recounting of some
of the major landmark discoveries.
© 2008 Elsevier Inc. All rights reserved.Viral oncology can trace its beginnings to observations made
during the early part of the 20th century when the transmissibility
of avian leukemia was ﬁrst described by Ellermann in Denmark in
1908 and the transmissibility of an avian sarcoma in chickens was
described by Rous in 1911 (Ellermann and Bang, 1908; Rous, 1911).
These ﬁndings were, however, not fully appreciated at the time, and
their full impact on virology and medicine was not recognized until
the 1950s with the identiﬁcation of murine tumor viruses that could
be studied experimentally in a controlled setting. In this context, the
1966 Nobel Prize in Medicine that recognized the work of Peyton
Rous that ﬁrst identiﬁed that a ﬁlterable agent from a sarcoma could
induce tumors in chickens was not awarded until nearly 50 years
after the initial discovery.
The ﬁrst evidence of mammalian tumor viruses came in the 1930s
with the work of Richard Shope who published several papers
demonstrating cell free transmission of tumors in rabbits. The ﬁrst
studies involved ﬁbromatous tumors found in the footpads of wild
cottontail rabbits that could be transmitted by injecting cell free
extracts into either wild or domestic rabbits. The relevant virus,
referred to as the Shope ﬁbroma virus, is now known to be a pox virus.
Other studies by Shope in this time period demonstrated that
cutaneous papillomatosis in wild cottontail rabbits could also be
transmitted by cell free extracts. In a number of cases, these benign
papillomas would progress spontaneously into squamous cell carci-
nomas in infected domestic or cottontail rabbits (Rous and Beard,
1935; Shope and Hurst, 1933). The ﬁeld of viral oncology, however,. Howley).
l rights reserved.was still not fully appreciated until the early 1950s with the discovery
of the murine leukemia viruses by Ludwig Gross (Gross, 1951) and of
the mouse polyoma virus by Gross, Stewart, and Eddy (Gross, 1953;
Stewart, 1953).
The discovery of tumor viruses in mice made it possible for
researchers to explore the role of viruses as cancer-inducing agents
though the medium of well controlled experiments with some
expectation that such studies would provide insights into the
mechanisms underlying human cancer and the possibility that some
proportion of human tumors might even have a viral etiology. The
Special Viral Cancer Program at the National Cancer Institute in the
late 1960s grew from this intense interest in viral oncology and the
hope that human tumor viruses would be identiﬁed through its
efforts. It is now recognized that between 15–20% of human cancers
can be directly associated with infection by certain viruses.
This special edition of Virology is focused on the small DNA tumor
viruses, which include the polyomaviruses, the adenoviruses, and the
papillomaviruses. It should be noted that the polyomaviruses and
papillomaviruses were originally classiﬁed together as different
genera of the papovaviruses (pa = papillomavirus; po = polyomavirus;
and va = vacuolating virus for SV40) because of similar morphology by
electron microscopy. Indeed it was not until genome comparison
studies of the late 1970s and early 1980s that the polyomaviruses and
papillomaviruses were recognized as distinct families of viruses. It
should also be noted that the small DNA viruses do not include all of
the types of DNA viruses that are associated with naturally occurring
tumors. Other DNA viruses associated with human cancers are the
herpesviruses (Epstein–Barr Virus and Kaposi's Sarcoma Herpesvirus)
and the hepadnaviruses (Hepatitis B virus).
Table 1
Landmark discoveries Involving the small DNA tumor viruses
Year Discovery Key references
1933 First mammalian tumor virus (CRPV) (Shope and Hurst, 1933)
1953 Discovery of the murine polyomavirus (Gross, 1953; Stewart, 1953)




1973 First restriction map of a virus (SV40) (Danna et al., 1973)
1977 RNA splicing (Berget et al., 1977; Chow et al.,
1977)
1978 First animal virus genome sequence (SV40) (Fiers et al., 1978; Reddy et al.,
1978)
1979 First mammalian viral vector (SV40) (Hamer and Leder, 1979;
Mulligan et al., 1979)
1979 Discovery of p53 (Lane and Crawford, 1979;
Linzer and Levine, 1979)
1979 In vitro viral DNA replication
systems leading to identiﬁcation of
mammalian DNA replication factors
(Challberg and Kelly, 1979)
1981 Identiﬁcation of polyadenylation signal (Fitzgerald and Shenk, 1981)
1981 Transcriptional enhancers (Banerji et al., 1981; Benoist
and Chambon, 1981)
1983 Identiﬁcation of Src as a target of PyMT (Courtneidge and Smith, 1983)
1983 Discovery of speciﬁc HPV types in
cervical cancer
(Boshart et al., 1984;
Durst et al., 1983)
1983 Identiﬁcation of speciﬁc
transcriptional factors (SP1)
(Dynan and Tjian, 1983)
1983 Viral down modulation of Class I
histocompatibility genes
(Schrier et al., 1983)
1983 Oncogene cooperation (Ad E1A and E1B) (Van den Elsen et al., 1983)
1984 Nuclear trafﬁcking sequences (Kalderon et al., 1984;
Lanford and Butel, 1984)
1986 Discovery of E2F (Kovesdi et al., 1986)
1988 Discovery that DNA TV oncogenes target
cellular tumor suppressor genes (pRB)
(DeCaprio et al., 1988;
Whyte et al., 1988)
1989 Development of virus like particles
for DNA viruses (Py)
(Salunke et al., 1989)
1990 Identiﬁcation of protein phosphatase
2A as a target of the polyomavirus
small T antigens
(Pallas et al., 1990;
Walter et al., 1990)
1993 Identiﬁcation of the ﬁrst mammalian
E3 ubiquitin-protein ligase (E6AP)
(Scheffner et al., 1993)
2006 FDA approved HPV VLP based
preventive vaccine
(Koutsky et al., 2002)
2008 Discovery of the Merkel cell polyomavirus (Feng et al., 2008)
257MinireviewThe focus by tumor virologists on the above-noted small DNA
tumor viruses can be traced back forty years to the ﬁrst DNA tumor
virus meeting that was held at the Cold Spring Harbor Laboratories in
August, 1969, the ﬁrst year that part of the annual Tumor Virus
meeting was devoted to reports of research on the DNA tumor viruses.
The organizers of this ﬁrst, annual meeting on the DNA tumor viruses
were Carel Mulder, Joe Sambrook and James D. Watson. Most of the
abstracts from that meeting involved SV40, polyomavirus and
adenovirus.1 During the same year Watson initiated a focus on
tumor virus research at the Cold Spring Harbor Laboratories with the
recruitment of Joe Sambrook and other young virologists, who began
to work on SV40 and the adenoviruses. The papillomaviruses did not
become a regular feature of this meeting until the late 1970s following
the successful cloning of papilloma viral genomes by recombinant
DNA techniques.
Many of the most important developments in modern molecular
biology derive from studies in viral oncology. Although this article will
focus on the discoveries that have come from studies of the small DNA
tumor viruses, it should be noted that the RNA tumor viruses led to the
discovery of reverse transcriptase by Howard Temin and David
Baltimore and the concept of oncogenes. Table 1 provides a list of1 We are grateful to Terry Grodzicker and Clare Clark at the Cold Spring Harbor
Laboratories for providing us a copy of the abstract book of the 1969 Tumor Virus
Meeting held at Cold Spring Harbor.major discoveries made at the hands of an analysis of small DNA
viruses. In addition to the discoveries of the ﬁrst papillomavirus
(CRPV) in 1933, the murine polyomavirus in 1953 and SV40 in 1960,
Table 1 provides an accounting of landmark discoveries that can be
attributed to the DNA tumor viruses.
The DNA tumor viruses provided vital tools for molecular
biologists to study complex nuclear events in mammalian cells in
the 1970s and the 1980s. Indeed, they continue to do so. Studies of
these small DNA viruses were fundamental in the development of
recombinant DNA technology. SV40 DNAwas the ﬁrst viral genome for
which a restriction endonuclease map was developed and the ﬁrst to
be sequenced in its entirety. Such studies were soon followed by the
completion of sequencing and gene mapping of murine polyomavirus
and the human adenoviruses.
A major focus of the small DNA tumor virus ﬁeld was and still is
cellular transformation. Studies from Fried using a temperature
sensitive murine polyomavirus established that the virus encodes a
gene responsible for the transformed phenotype (Fried, 1965). More
relevant still, transformation studies with the polyomaviruses have
identiﬁed genes and pathways that have proven critical in human
cancer. The murine polyomavirus encodes three different transform-
ing proteins (small, middle and large T antigens) and among the
targets of these viral oncogenes are Src kinase, PI3 kinase, shc, and
protein phosphatase 2A. Perhaps the major contribution of the small
DNA viruses to an understanding of human cancer has been the
recognition that some of the viral oncogenes encoded by these viruses
are transforming because they bind and functionally perturb certain
established tumor suppressor genes. This was ﬁrst shown for the E1A
oncoprotein of adenovirus and the retinoblastoma gene product (pRB)
(Whyte et al., 1988), followed soon thereafter by studies with SV40
large T-antigen (DeCaprio et al., 1988) and HPV16 E7 (Dyson et al.,
1989).
A discovery that also emerged from studies of the small DNA tumor
viruses and that is the most revealing of a mechanism underlying
much of human cancer development was that of p53 in 1979 as a
protein bound tightly to SV40 large T-antigen (Lane and Crawford,
1979; Linzer and Levine, 1979). The signiﬁcance of the interaction of
p53with SV40 large T was not appreciated until the late 1980swhen it
became clear that, like pRB, p53 is also a tumor suppressor gene, and
its function is compromised by binding to T Ag. Moreover, like pRB,
p53 is also targeted by oncoproteins encoded by other small DNA
viruses. The 55 kDa product encoded by the adenovirus E1B gene
(Sarnow et al., 1982) and the high-risk HPV E6 proteins (Werness et al.,
1990) both bind and compromise p53 function. Thus a penetrant
theme among the small DNA tumor viruses is that key activities of
some of their oncoproteins result from an ability to target and
inactivate certain cellular tumor suppressor gene products. The viral
oncoproteins of these small DNA viruses target many other cellular
proteins and perturb numerous other homeostatic signal transduction
pathways on the way to eliciting a neoplastic phenotype, as is well
documented in the other articles in this volume.
Another major discovery relevant to cellular transformation was
theﬁnding that certain oncogene products cooperatewith one another
in eliciting a transformed phenotype. This observation emerged
initially from studies with the adenoviruses showing a transformation
requirement for E1A as well as E1B (Van den Elsen et al., 1983). The
notion of cooperating oncogenes was subsequently extended to
cellular oncogenes, such as myc and ras (Land et al., 1983). Another
observation that emerged from studies of the adenoviruses and
directly relevant to cancer was the ﬁnding that Ad E1A contributes to
tumorigenesis by the down modulation of expression of the major
histocompatibility genes (Schrier et al., 1983). This implied that
suppression of an immune responsewas needed before tumorigenesis
could occur. Moreover, work from the Nevins laboratory led to the
identiﬁcation of the E2F family of transcription factors critical to cell
cycle regulation (Kovesdi et al., 1986). Subsequent studies in the ﬁeld
258 Minireviewidentiﬁed the E2F factors as the targets of pRB (and the related p107
and p130 pocket proteins) (Dyson, 1998).
In addition to observations that revealed roles in cancer develop-
ment for certain tumor suppressing and oncogenes and signal;
transduction pathways in which they participate, fundamental
discoveries regarding the nature and mechanisms underlying basic
mammalian cell processes such as transcription and DNA replication
emerged from studies of these viruses. Among these include the
discovery of mRNA splicing with adenovirus (Berget et al., 1977;
Chow et al., 1977). Studies of SV40 and polyomavirus transcription
also led to the identiﬁcation of DNA-based transcriptional enhancer
elements (Banerji et al., 1981; Benoist and Chambon, 1981), and
these, in turn, led to the identiﬁcation of speciﬁc DNA binding
transcription factors (Dynan and Tjian, 1983). Studies of SV40
transcription also led to the elucidation of polyadenylation signals
(Fitzgerald and Shenk, 1981). The ﬁrst In vitro mammalian DNA
replication systems was established for adenovirus DNA (Challberg
and Kelly, 1979), subsequently for SV40 DNA, and eventually for the
papillomavirus DNAs (Li and Kelly, 1984; Yang et al., 1991). These
studies have contributed to the identiﬁcation and functional under-
standing of a number of mammalian cell DNA replication factors. In
addition, studies of SV40 large T-antigen led to the identiﬁcation of
protein nuclear localization and trafﬁcking sequences (Kalderon et al.,
1984; Lanford and Butel, 1984).
Major contributions to understanding the nature of in vivo protein
degradation and the ubiquitin pathway came from studies of the high
risk HPVs associated with human cancer. Studies with the E6 and p53
led to the identiﬁcation p53 as the ﬁrst mammalian substrate of the
ubiquitin-dependent polypeptide degradation system (Scheffner et
al., 1990) and the characterization of E6AP as the ﬁrst mammalian
ubiquitin E3 protein-ligase (Scheffner et al., 1993). Subsequent studies,
including those with the adenoviruses (Querido et al., 1997),
established ubiquitin-mediated proteolysis as a process regularly
employed by tumor viruses.
Certain small DNA tumor viruses cause disease in man. Indeed,
the 2008 Nobel Prize in Medicine recognized Harald zur Hausen for
his discovery of speciﬁc HPVs associated with human cervical cancer.
Speciﬁcally using non-stringent hybridization conditions, he and his
colleagues identiﬁed two new HPV types (HPV16 and HPV18) in
cervical cancer specimens and demonstrated their association with
carcinomas and precancerous lesions of the cervix (Boshart et al.,
1984; Durst et al., 1983). The same cervical cancer-associated HPVs
are also associated other anogenital cancers and with approximately
20% of upper airway cancers. Another subset of HPV (the beta
genus), members of which were ﬁrst identiﬁed and studied by
Gerard Orth and Stephania Jablonska in patients with epidermodys-
plasia verruciformis (Orth, 1978), may also have a role in skin
cancers. If they are etiologic agents in these cancers, their role may
involve a hit and run mechanism, since the viral DNAs are not
generally found in these tumors.
Although SV40 and the human polyomaviruses have been
important models for studying cellular transformation, their potential
role in human cancers has been less clear. There have been periodic
reports dating back to the 1970s claiming the presence of SV40 DNA in
a variety of different human cancers, including osteosarcomas,
mesotheliomas, pancreatic tumors and brain tumors. This has been
a very controversial area and one that has received considerable
scrutiny from investigators in the ﬁeld and by the National Cancer
Institute (Poulin and DeCaprio, 2006; Shah, 2007). The recent
identiﬁcation of a new human polyomavirus in Merkel cell cancers,
however, appears to be a solid candidate for behaving as a human
cancer virus (Feng et al., 2008).
Methods such a single DNA molecule sequencing and high density
SNP arrays for readily detecting very small amounts of viral DNA
integrated into host cell genomes now exist. With their application to
searches for new DNA tumor viruses in human tumors, other new,small DNA human tumor-associated viruses might be discovered in
the years ahead.References
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